Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Omnix Medical","sponsor":"EIC Accelerator Programme","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omnix Medical Wins \u20ac10.8M in EIC Accelerator Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Omnix Medical

    Menu

    Omnix Medical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Omnix Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Omnix Medical Wins €10.8M in EIC Accelerator Funding

              Details:

              Funding secures the advancement of Omnix Medical’s lead compound OMN6 through Phase I and II clinical trials. OMN6 is a novel antimicrobial peptide for treating life-threatening infections caused by Gram-negative bacteria.

              Lead Product(s): OMN6

              Therapeutic Area: Infections and Infectious Diseases Product Name: OMN6

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: EIC Accelerator Programme

              Deal Size: $13.0 million Upfront Cash: Undisclosed

              Deal Type: Funding January 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY